HC Wainwright cuts target for Pacira BioSciences stock to USD 36.50

Published on 10/20/2026 at 22:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 192.40 million. Pacira BioSciences stock costs EUR 32.30 on October 20, 2026, up 0.94 percent versus the Frankfurt close.

Analyst target and reporting date

HC Wainwright cut its Pacira target to USD 36.50 on October 9, 2026.
Second-quarter revenue reached USD 192.40 million in the period ended June 30, 2026.
Pacira BioSciences stock costs EUR 32.30 at Lang & Schwarz on October 20, 2026 at 9:57 p.m. CEST, 0.94 percent above the Frankfurt close.
Pacira is scheduled to report third-quarter 2026 earnings on October 29, 2026.

PCRX, US6951271005, Illustration mit AI erstellt.

HC Wainwright cut its target for Pacira BioSciences from USD 38.00 to USD 36.50 and downgraded the stock to Hold in a report dated October 9, 2026, MarketBeat reported. The USD 36.50 target lies 0.33 percent above the USD 36.38 Nasdaq price at the October 20, 2026 close. Pacira BioSciences stock was trading at EUR 32.30 at Lang & Schwarz on October 20, 2026 at 9:57 p.m. CEST, 0.94 percent above the Frankfurt close of October 16, 2026 at EUR 32.00.

Second-quarter revenue reached USD 192.40 million

Pacira reported USD 192.40 million in second-quarter revenue for the period ended June 30, 2026, an increase of 6.20 percent from the year-ago quarter. Adjusted earnings per share came to USD 0.73, beating the USD 0.64 consensus estimate, while Exparel sales rose 3.00 percent to USD 147.80 million, according to Zacks on August 5, 2026.

The same report said Pacira reduced its full-year 2026 revenue outlook to USD 735.00 million to USD 760.00 million from USD 745.00 million to USD 770.00 million. Adjusted gross margin guidance remained 77.00 percent to 79.00 percent, leaving the outlook below the earlier sales range even as quarterly revenue expanded.

What does the 52-week range show?

The Nasdaq quote placed Pacira's 52-week range at USD 18.80 to USD 36.67 on October 20, 2026. The USD 36.38 home-market price therefore stood 0.79 percent below the high, while the market capitalization was USD 1.5 billion and the trailing price-to-earnings ratio was 103.52.

When will Pacira report again?

Pacira is scheduled to report third-quarter 2026 earnings on October 29, 2026, according to Barron's. The next report will matter because the revised annual outlook covers only USD 735.00 million to USD 760.00 million in revenue after the iovera divestiture.

On October 8, 2026, Pacira had announced that Viatris agreed to acquire the company, with completion expected by the end of 2026, Pacira BioSciences said.

Pacira stock stays near its yearly high

The combination of a USD 36.50 target and a USD 36.67 yearly high leaves little separation between the analyst reference and the recent market peak. For investors, the October 29 earnings date now provides the next scheduled test of revenue execution and the reduced 2026 outlook. The further course of trading is shown by the continuously updated real-time quote of Pacira BioSciences stock.